Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Q2 Revenues Fall, Loss Rises

NEW YORK, July 22 (GenomeWeb News) - Compugen on Wednesday reported a sharp decline in revenues and a higher net loss for the second quarter of 2004, as it continues implementing its plan to focus on its therapeutic protein pipeline.

 

The Tel Aviv, Israel-based firm posted a net loss of $3.4 million, or $.12 per share, versus a net loss of $2.4 million, or $.09 per share, for the second quarter of 2003. Its revenues for the quarter declined to $984,000 from $2.9 million in the comparable period a year ago.

 

The results reflect Compugen's decision in the first quarter to cease marketing its LEADS bioinformatics platform and redirect its resources toward therapeutic protein discovery. The company also is in the process of divesting software product lines and reducing its efforts in tools and services. Last summer, Compugen sold its Bioaccelerator product line to Bioacceleration Ltd.

 

As of June 30, 2004, Compugen had $54.8 million in cash, cash equivalents and marketable securities.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.